SOLARA

** Shares of Shilpa Medicare SHME.NS rise 6.7% to 880 rupees, their biggest one-day gain since Oct. 8

** Pharma co's Q2 consol profit and revenue rises over 11-fold and 13%, respectively, helped by traction in its emerging markets and formulation segment

** SHME sees third-busiest day in nearly three months, with over 391,000 shares traded

** Stock extends YTD gains to 166% vs 122% gain in peer Solara Active Pharma SOLA.NS

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Solara Active Pharma SOLA.NS climb as much as 5% to 850.65 rupees, its highest since Feb. 2022

** Co reported Q2 consol net profit of 80.1 mln rupees ($953,072.20) from net loss of 171.6 mln rupees a year ago

** SOLA was up 1.4% ahead of results

** About 2.5 mln shares traded, 3.3x the 30-day avg

** Stock last up 2.7%, extending YTD gains to ~151%

($1 = 84.0440 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Solara Active Pharma Sciences SOLA.NS drops 4.5%

** TPG Growth IV SF nearly halves stake to 4.44% from 8.60%

** Stock set to snap 9-day rally in which it gained ~30%

** Stock has jumped ~68% YTD, hitting an over 2-year high on Tues

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected]))

June 12 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• SOLARA ACTIVE PHARMA SCIENCES - ANNOUNCED CLOSURE OF ITS RIGHTS ISSUE FOR RAISING FUNDS UPTO 4.5 BILLION RUPEES

Source text for Eikon: ID:nBSE5xpMK4

Further company coverage: SOLA.NS

(([email protected];))

** Shares of Solara Active Pharma Sciences SOLA.NS rise as much as 3.9% before trimming some gains, last up 1.1% to 489.55 rupees

** The active pharmaceutical ingredients (API) maker said its Visakhapatnam facility completes U.S. FDA Inspection with Zero 483 observations

** Including session's gains, stock up 47% YTD, while peers Alembic Pharmaceuticals ALEM.NS and Laurus Labs LAUL.NS have gained 26% and 3.7%, respectively

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

May 20 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• SOLARA VISAKHAPATNAM FACILITY COMPLETES USFDA INSPECTION WITH ZERO INSPECTIONAL OBSERVATIONS

• INSPECTION ESTABLISHED SITE IS IN "ACCEPTABLE STATE OF COMPLIANCE"

• INSPECTION WITH ZERO FORM 483 INSPECTIONAL OBSERVATIONS FROM US FDA

Source text for Eikon: ID:nNSE2Jsyyn

Further company coverage: SOLA.NS

(([email protected];))

May 9 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• APPROVED RIGHTS ISSUE PRICE: 375 RUPEES PER RIGHTS EQUITY SHARE

• RIGHTS ISSUE SIZE FOR AN AMOUNT AGGREGATING TO 4.50 BILLION RUPEES

Source text for Eikon: ID:nBSE8NPD6K

Further company coverage: SOLA.NS

(([email protected];;))

March 25 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• APPROVED SALE OF 100% SHAREHOLDING IN SEQUENT PENEMS

Source text for Eikon: [ID:]

Further company coverage: SOLA.NS

(([email protected];))

March 8 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• NAMED ARUN KUMAR BASKARAN AS CFO

Further company coverage: SOLA.NS

(([email protected];))

** Shares of Solara Active Pharma Sciences SOLA.NS up 4.8% at 486.25 rupees

** API maker targets to double its operating profit by the end of fiscal 2025 from Q4 FY24, per transcript of post-earnings investor call made public post-market hours on Tuesday

** SOLA reported a Q3 loss vs profit on Feb. 14

** Trading volume 4.3x the 30-day moving average

** Stock up ~35% YTD after falling for three straight years

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Nov 14 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• APPROVED SALE OF LAND AND BUILDING BELONGING TO UNIT SEQUENT PENEMS

Source text for Eikon: ID:nNSE7hn5Ts

Further company coverage: SOLA.NS

(([email protected];;))

Oct 19 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• P V RAGHAVENDRA RAO APPOINTED CFO

Further company coverage: SOLA.NS

(([email protected];))

Aug 14 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• INDIA'S SOLARA ACTIVE PHARMA SCIENCES JUNE-QUARTER CONSOL NET LOSS 195.5 MILLION RUPEES VERSUS LOSS 164.3 MILLION RUPEES

• SOLARA ACTIVE PHARMA SCIENCES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.52 BILLION RUPEES VERSUS 3.3 BILLION RUPEES

Source text for Eikon: ID:nBSEbKFMmz

Further company coverage: SOLA.NS

(([email protected];))

Aug 7 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• SOLARA ACTIVE PHARMA SCIENCES LTD - INSPECTION ESTABLISHED THAT FACILITY IS IN AN "ACCEPTABLE STATE OF COMPLIANCE"

• SOLARA ACTIVE PHARMA SCIENCES LTD - INSPECTION CONCLUDED WITH ZERO FORM 483 INSPECTIONAL OBSERVATIONS FROM AGENCY

• SOLARA ACTIVE PHARMA SCIENCES - CURRENT INSPECTION CLASSIFICATION OF CUDDALORE SITE SHALL BE REINSTATED TO NO ACTION INDICATED

Source text for Eikon: ID:nNSE1hYBtD

Further company coverage: SOLA.NS

(([email protected];))

July 31 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• SOLARA ACTIVE PHARMA SCIENCES LTD - S HARIHARAN RESIGNS AS CFO

Source text for Eikon: ID:nNSEbp3VkD

Further company coverage: SOLA.NS

(([email protected];))

July 5 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• JITESH DEVENDRA RESIGNED AS MD

• NAMES POORVANK PUROHIT AS MD, CEO

Further company coverage: SOLA.NS

(([email protected];;))

June 30 (Reuters) - Solara Active Pharma Sciences Ltd SOLA.NS:

• TO CONSIDER PROPOSAL TO ISSUE EQUITY SHARES ON RIGHTS BASIS

Source text for Eikon: ID:nBSE6N2646

Further company coverage: SOLA.NS

(([email protected];))

** Shares of Solara Active Pharma Sciences Ltd SOLA.NS rise as much as 6.69% to 439.95 rupees, highest in seven weeks

** API maker reports a more two-fold Y/Y jump in March-qtr profit on a 5.5% increase in revenue from ops nFWN3790PL

** Core profit more than tripled

** Trading volume is 634,173 shares as of 2:45 p.m. IST, nearly five times the 30-day avg - Refinitiv IBES data

($1 = 81.7800 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))